More recently, Varshavi and colleagues, described a molecular association between CRC that present oncogenic KRAS mutation and glutamine metabolism, since these cells exhibit special metabolic phenotypes, including differences in glycolysis, glutamine utilization and AA metabolism [33]. Here, KRAS is linked to colorectal carcinoma.